Quick Answer
Both are NICE-approved for NHS use within specialist weight management services, but real-world availability varies significantly by region. Many patients access these medications privately.
Detailed Answer
Both Mounjaro and Wegovy have received NICE approval for use on the NHS, which is a significant milestone. However, NICE approval does not guarantee immediate or universal NHS access.
Mounjaro (tirzepatide) received NICE approval for weight management in December 2024 (TA1026). The NHS rollout is phased: from March 2025, specialist weight management services were required to fund access for eligible patients. A broader phased rollout to primary care is being guided by NHS England's interim commissioning policy, with an initial implementation period of up to three years.
Wegovy (semaglutide) received NICE approval for weight management via TA875 in March 2023. NHS availability has been expanding but remains inconsistent across different regions and Integrated Care Boards (ICBs).
In practice, many patients currently access these medications privately through GPhC-registered online pharmacies. Private access requires an online medical consultation but does not require a GP referral or NHS waiting times.
If you want to check NHS availability in your area, contact your local Integrated Care Board (ICB) or speak to your GP about referral to a specialist weight management service.